Indeed, the success of anti-tumour defence is determined by the ability of CD8+ T cells to overcome additional barriers that they may encounter within the TME posed by tumour cells, fibrotic stroma, T regulatory (Treg) cells, myeloid cells, inhibitory cytokines, and other stroma components that act to mitigate the anti-tumour response [5]. This evidence concerns the gene CD8A and neoplasm.